bigfoot-biomedical-2

Bigfoot Biomedical is a company that MD+DI readers should be quite familiar with by now. In 2017, the diabetes company was selected as the readers' choice for Medtech Company of the Year. The company is developing products to optimize insulin dosing and provide automated insulin delivery for people with insulin-requiring diabetes. Read More →

Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced today that it has secured new financing of up to $57 million from Madryn Asset Management LP, an alternative asset management firm focused on investments in innovative health care companies. Read More →

Milpitas, Calif.-based Bigfoot said in a news release that the proceeds will support product development and the regulatory pathway for its Bigfoot Unity system as a part of the Bigfoot Unity Diabetes Management Program. Read More →

Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers... Read More →

Milpitas, CA, and Pittsburgh, PA, August 1, 2019 – Bigfoot Biomedical, Inc., and Allegheny Health Network (AHN) – a Highmark Health company – announced today a collaboration to further advance Bigfoot Biomedical’s first-in-kind data-driven solutions for optimizing the dosing and delivery... Read More →